DMRA vs WRD
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
DMRA · Damora Therapeutics$23.70 ▲ 8.42%
WRD · WeRide$4.46 ▲ 10.40%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- DMRA +37.4%
- WRD -45.4%
Head to head
| Metric | DMRA | WRD |
|---|---|---|
| Price | $23.70 | $4.46 |
| Change today | ▲ 8.42% | ▲ 10.40% |
| Market cap | $1.47B | $1.47B |
| Return, 3 months | -19.8% | -29.4% |
| Return, year to date | +3.0% | -48.6% |
| Return, 1 year | +378.8% | -44.2% |
| P/E (TTM) | 13.9 | – |
| P/B | 4.0 | 1.5 |
| P/E percentile vs own 5y | 4th | 89th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +82.2% |
| Net profit growth (YoY) | -807.0% | +1.4% |
| Gross margin | – | 32.8% |
| Operating margin | – | -216.4% |
| Net margin | – | -199.0% |
| Return on equity | -132.8% | -25.7% |
| Analyst target vs. price | +96.9% | +191.5% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 60 | 48 |
| 30-day volatility | 58.4% | 69.8% |
| Max drawdown, 1 year | -46.9% | -65.5% |
| Trend read | Leaning bullish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- WRD is the largest of the group by market value.
- DMRA has returned the most over the past year.
- DMRA has been the calmest stock over the last 30 days.